For years, Washington has promised to enhance healthcare but only delivered escalating costs and complicated systems where middlemen profited while patients struggled with bills. President Trump, unlike many career politicians such as Joe Biden and Kamala Harris, is stepping in to cut out these middlemen, effectively putting patients back in control.
This initiative is behind Trump’s promotion of direct-to-consumer healthcare options, like Trump Rx. Instead of requiring permission from insurance companies, pharmacy benefit managers (PBMs), and bureaucrats, Trump Rx enables patients to access medications directly from manufacturers, complete with clear pricing and fewer hurdles. It’s about time something straightforward like this emerged.
The true issues stem from middlemen, rather than doctors or pharmaceutical companies. Pharmacy benefit managers (PBMs) are positioned between patients, pharmacies, insurance providers, and drug manufacturers, often skewing the system to benefit themselves. Their business model tends to create higher list prices, bigger rebates, and more convoluted rewards, where ultimately, patients suffer while PBMs profit.
President Trump is taking significant steps to dismantle that structure.
Recently, he signed legislation aimed at curtailing the payment schemes used by PBMs. The goal is to free patients from being shackled to inflated drug prices. This matters because when PBMs benefit from elevated list prices, they steer insurance plans towards costlier drugs despite the availability of cheaper, equally effective alternatives. By severing this connection, President Trump is addressing the twisted incentives that have inflated prices for many Americans.
This situation isn’t just an abstract policy discussion; it’s a concrete assault on a flawed system.
Moreover, the efforts are ongoing. Under Trump’s guidance, the Federal Trade Commission is shifting its focus towards consumer protection rather than catering to corporate interests. With Andrew Ferguson as the lead on healthcare competition, the FTC is actively working against PBM misconduct that distorts market competition and escalates costs.
This includes interventions to challenge dominant PBMs, like in the case of Express Scripts—favoring pricier medications over cheaper alternatives simply due to greater rebates. When PBMs leverage their market control to suppress competition and inflate profits, it resembles cartel behavior, and Trump’s FTC is treating it as such.
As anticipated, those benefitting from the current system are upset.
PBMs and their supporters claim that these reforms will “ruin the system,” which essentially means they’re concerned about losing their revenue sources. For years, they have thrived in obscurity, hoping that Americans wouldn’t see who was truly inflating costs at the pharmacy. But Trump has seen through this and responded.
This is what America First healthcare looks like: fewer middlemen, more transparency, and genuine competition, putting patients back in charge.
While Democrats cater to large insurance donors, Trump continues to challenge entrenched interests and stand by average Americans. Whether it’s negotiating fairer trade deals or exposing price manipulation by intermediaries, the goal remains the same: lower costs and improved care.
Healthcare doesn’t require more “experts” from Washington; it needs a bold approach targeting those intermediaries that caused issues in the first place. Mr. Trump has committed to taking drastic measures, and he’s following through. Americans certainly have the upper hand now.
